BIIB vs. HLN: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at BIIB and HLN, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
BIIB is a standard domestic listing, while HLN trades as an American Depositary Receipt (ADR), offering U.S. investors access to its foreign-listed shares.
| Symbol | BIIB | HLN |
|---|---|---|
| Company Name | Biogen Inc. | Haleon plc |
| Country | United States | United Kingdom |
| GICS Sector | Health Care | Consumer Staples |
| GICS Industry | Biotechnology | Personal Care Products |
| Market Capitalization | 22.13 billion USD | 40.25 billion USD |
| Exchange | NasdaqGS | NYSE |
| Listing Date | September 17, 1991 | July 25, 2022 |
| Security Type | Common Stock | ADR |
Historical Performance
This chart compares the performance of BIIB and HLN by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | BIIB | HLN |
|---|---|---|
| 5-Day Price Return | -2.76% | -0.84% |
| 13-Week Price Return | 13.49% | -11.02% |
| 26-Week Price Return | 15.50% | -14.92% |
| 52-Week Price Return | -17.66% | -12.92% |
| Month-to-Date Return | 7.77% | -0.63% |
| Year-to-Date Return | -1.28% | -12.48% |
| 10-Day Avg. Volume | 1.99M | 16.58M |
| 3-Month Avg. Volume | 1.51M | 14.61M |
| 3-Month Volatility | 37.07% | 19.16% |
| Beta | 0.12 | 0.45 |
Profitability
Return on Equity (TTM)
BIIB
9.04%
Biotechnology Industry
- Max
- 97.92%
- Q3
- 11.99%
- Median
- -19.30%
- Q1
- -51.29%
- Min
- -132.03%
BIIB’s Return on Equity of 9.04% is on par with the norm for the Biotechnology industry, indicating its profitability relative to shareholder equity is typical for the sector.
HLN
3.26%
Personal Care Products Industry
- Max
- 33.29%
- Q3
- 19.04%
- Median
- 10.69%
- Q1
- 3.26%
- Min
- -10.45%
HLN’s Return on Equity of 3.26% is on par with the norm for the Personal Care Products industry, indicating its profitability relative to shareholder equity is typical for the sector.
Net Profit Margin (TTM)
BIIB
15.31%
Biotechnology Industry
- Max
- 73.34%
- Q3
- 18.98%
- Median
- -12.96%
- Q1
- -105.72%
- Min
- -259.82%
BIIB’s Net Profit Margin of 15.31% is aligned with the median group of its peers in the Biotechnology industry. This indicates its ability to convert revenue into profit is typical for the sector.
HLN
12.84%
Personal Care Products Industry
- Max
- 14.65%
- Q3
- 10.84%
- Median
- 9.29%
- Q1
- 5.35%
- Min
- -0.14%
A Net Profit Margin of 12.84% places HLN in the upper quartile for the Personal Care Products industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
BIIB
20.80%
Biotechnology Industry
- Max
- 78.85%
- Q3
- 21.90%
- Median
- -13.30%
- Q1
- -109.94%
- Min
- -278.10%
BIIB’s Operating Profit Margin of 20.80% is around the midpoint for the Biotechnology industry, indicating that its efficiency in managing core business operations is typical for the sector.
HLN
19.64%
Personal Care Products Industry
- Max
- 19.64%
- Q3
- 16.46%
- Median
- 12.80%
- Q1
- 8.01%
- Min
- 2.98%
An Operating Profit Margin of 19.64% places HLN in the upper quartile for the Personal Care Products industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | BIIB | HLN |
|---|---|---|
| Return on Equity (TTM) | 9.04% | 3.26% |
| Return on Assets (TTM) | 5.43% | 1.58% |
| Net Profit Margin (TTM) | 15.31% | 12.84% |
| Operating Profit Margin (TTM) | 20.80% | 19.64% |
| Gross Profit Margin (TTM) | 75.43% | 60.75% |
Financial Strength
Current Ratio (MRQ)
BIIB
2.50
Biotechnology Industry
- Max
- 16.97
- Q3
- 8.39
- Median
- 4.11
- Q1
- 2.64
- Min
- 0.74
BIIB’s Current Ratio of 2.50 falls into the lower quartile for the Biotechnology industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
HLN
0.87
Personal Care Products Industry
- Max
- 4.03
- Q3
- 2.73
- Median
- 1.76
- Q1
- 1.16
- Min
- 0.76
HLN’s Current Ratio of 0.87 falls into the lower quartile for the Personal Care Products industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio (MRQ)
BIIB
0.36
Biotechnology Industry
- Max
- 1.92
- Q3
- 0.79
- Median
- 0.12
- Q1
- 0.00
- Min
- 0.00
BIIB’s Debt-to-Equity Ratio of 0.36 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
HLN
0.53
Personal Care Products Industry
- Max
- 1.80
- Q3
- 0.78
- Median
- 0.30
- Q1
- 0.04
- Min
- 0.00
HLN’s Debt-to-Equity Ratio of 0.53 is typical for the Personal Care Products industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
BIIB
4.35
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.03
- Median
- -9.59
- Q1
- -65.05
- Min
- -163.11
BIIB’s Interest Coverage Ratio of 4.35 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
HLN
8.00
Personal Care Products Industry
- Max
- 96.53
- Q3
- 59.91
- Median
- 22.25
- Q1
- 7.85
- Min
- -3.28
HLN’s Interest Coverage Ratio of 8.00 is positioned comfortably within the norm for the Personal Care Products industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | BIIB | HLN |
|---|---|---|
| Current Ratio (MRQ) | 2.50 | 0.87 |
| Quick Ratio (MRQ) | 1.79 | 0.63 |
| Debt-to-Equity Ratio (MRQ) | 0.36 | 0.53 |
| Interest Coverage Ratio (TTM) | 4.35 | 8.00 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
BIIB
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BIIB currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
HLN
0.72%
Personal Care Products Industry
- Max
- 4.99%
- Q3
- 2.70%
- Median
- 1.98%
- Q1
- 0.95%
- Min
- 0.00%
HLN’s Dividend Yield of 0.72% is in the lower quartile for the Personal Care Products industry. This suggests the company’s strategy likely favors retaining earnings for growth over providing a high dividend income.
Dividend Payout Ratio (TTM)
BIIB
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BIIB has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
HLN
954.40%
Personal Care Products Industry
- Max
- 221.40%
- Q3
- 137.27%
- Median
- 70.48%
- Q1
- 51.10%
- Min
- 0.00%
At 954.40%, HLN’s Dividend Payout Ratio is exceptionally high, exceeding the typical range for the Personal Care Products industry. While this provides a significant return to shareholders, it may limit funds for reinvestment and could be difficult to sustain.
Dividend at a Glance
| Symbol | BIIB | HLN |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.72% |
| Dividend Payout Ratio (TTM) | 0.00% | 954.40% |
Valuation
Price-to-Earnings Ratio (TTM)
BIIB
14.47
Biotechnology Industry
- Max
- 40.44
- Q3
- 39.37
- Median
- 22.12
- Q1
- 15.76
- Min
- 3.48
In the lower quartile for the Biotechnology industry, BIIB’s P/E Ratio of 14.47 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
HLN
20.40
Personal Care Products Industry
- Max
- 46.28
- Q3
- 31.71
- Median
- 22.50
- Q1
- 20.20
- Min
- 11.79
HLN’s P/E Ratio of 20.40 is within the middle range for the Personal Care Products industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
BIIB
2.22
Biotechnology Industry
- Max
- 92.67
- Q3
- 41.36
- Median
- 8.45
- Q1
- 4.46
- Min
- 0.97
In the lower quartile for the Biotechnology industry, BIIB’s P/S Ratio of 2.22 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
HLN
2.62
Personal Care Products Industry
- Max
- 2.59
- Q3
- 2.35
- Median
- 1.92
- Q1
- 1.18
- Min
- 0.00
With a P/S Ratio of 2.62, HLN trades at a valuation that eclipses even the highest in the Personal Care Products industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.
Price-to-Book Ratio (MRQ)
BIIB
1.04
Biotechnology Industry
- Max
- 22.72
- Q3
- 10.68
- Median
- 4.55
- Q1
- 2.44
- Min
- 0.59
BIIB’s P/B Ratio of 1.04 is in the lower quartile for the Biotechnology industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
HLN
2.11
Personal Care Products Industry
- Max
- 12.00
- Q3
- 6.22
- Median
- 2.84
- Q1
- 1.70
- Min
- 1.12
HLN’s P/B Ratio of 2.11 is within the conventional range for the Personal Care Products industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | BIIB | HLN |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 14.47 | 20.40 |
| Price-to-Sales Ratio (TTM) | 2.22 | 2.62 |
| Price-to-Book Ratio (MRQ) | 1.04 | 2.11 |
| Price-to-Free Cash Flow Ratio (TTM) | 11.99 | 13.68 |